In this context, using MALDI-TOF–MS, Biskup and colleagues developed a serum N-glycan score (GLYCOV) capable of differentiating between early-stage ovarian cancer patients and healthy volunteers, with a sensitivity of 95%, which was 35% higher than that of CA125. The gene discussed is MUC16; the disease is ovarian carcinoma.